Trials / Completed
CompletedNCT04443751
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase I, Multicenter, Open-label Study of SHR-1702 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and preliminary efficacy of escalating doses of SHR-1702 monotherapy in relapsed/refractory AML and intermediate-high risk MDS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1702 | SHR-1702 monotherapy, administered IV |
Timeline
- Start date
- 2020-09-10
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2020-06-23
- Last updated
- 2023-08-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04443751. Inclusion in this directory is not an endorsement.